TORONTO, ONTARIO -- (Marketwire) -- 03/19/13 -- Trimel Pharmaceuticals Corporation (TSX: TRL) (the "Company" or "Trimel") today announced that. Trimel Biopharma SRL ("Trimel SRL"), a wholly-owned subsidiary of Trimel, has entered into an agreement to partner with a privately-held European company to develop single dose and fixed dose combinations of a portfolio of established active pharmaceutical ingredients for the treatment of a variety of respiratory disorders utilizing Trimel SRL's award-winning inhalation technology, called TriVair.
As part of this transaction, Trimel SRL will gain rights to all know-how and intellectual property developed for the applicable products for territories outside of the European Union, Russia and Ukraine. Trimel SRL's development partner will be granted rights to the products developed under the agreement in these markets. Royalties will be payable by the parties to each other in connection with revenues received by each party (or any licensees) in their respective territories in connection with any developed products developed under the agreement.
TriVair is a disposable, single unit dose, dry powder inhalation drug delivery technology platform with applications for both nasal and pulmonary dosing. TriVair, through in vitro cascade impactor studies, demonstrated that it may provide patients suffering from respiratory disorders with up to 2.5 times greater drug deposition in the lung as compared to metered dose inhalers. It is hoped that greater lung deposition of medications will result in equal efficacy to currently marketed asthma medications with reduced drug load. TriVair is also designed to provide patients and their caregivers with immediate visual feedback to ensure that the dose has been accurately administered.
About Trimel and Trivair
Trimel Pharmaceuticals Corporation (TSX: TRL) - Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. CompleoTRT, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has successfully completed its pivotal Phase III study for the treatment of male hypogonadism, a condition commonly referred to as "Low T", and Trimel is preparing to submit its New Drug Application with the FDA in the coming months. For more information, please visit www.trimelpharmaceuticals.com.
In November 2009, Trimel SRL acquired assets of Keldmann Healthcare A/S, which has subsequently been rebranded as TriVair. TriVair was the 2009 European Drug Delivery Devices Product Differentiation Innovation of the Year award winner. TriVair is a disposable single unit dose dry powder inhalation drug delivery technology platform with applications for both nasal and pulmonary dosing. TriVair's patented drug delivery technology may provide significant benefits to patients suffering from certain respiratory disorders.
Notice regarding forward-looking statements:
This press release contains forward-looking information. This forward-looking information is not based on historical facts but rather on the expectations of the Company's management regarding the future growth of the Company and its respective results of operations, performance and business prospects and opportunities. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. This press release uses words such as "believe", "expect", "would", "will", "expects", "anticipates", "intends", "estimates", or similar expressions to identify forward-looking information. Such forward-looking information reflects the current beliefs of the Company's management based on information currently available to them.
Forward-looking information included in this press release is based, in part, on factors and assumptions that may change, thus causing actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information. Such factors and assumptions include that: the Company will achieve, sustain or increase profitability, and will be able to fund its operations with existing capital, and/or it will be able to raise additional capital to fund operations; the Company will be able to attract and retain key personnel; the Company will be able to acquire any necessary technology or businesses and effectively integrate such acquisitions; the Company will be successful in developing and clinically testing products under development; the Company will be successful in obtaining all necessary approvals for commercialization of its products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; the results of continuing and future safety and efficacy studies by industry and government agencies relating to the Company's products will be favourable; the Company's products will not be adversely impacted by competitive products and pricing; raw materials and finished products necessary for the Company's products will be available; the Company will be able to maintain and enforce the protection afforded by any patents or other intellectual property rights; the Company's products will be successfully licensed to third parties to market and distribute such products on favourable terms; the Company's key strategic alliances, out licensing and partnering arrangements, now and in the future, will remain in place and in force; the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiaries will remain constant and the Company will not become subject to any material legal proceedings. The Company cautions that the foregoing list of assumptions is not exhaustive.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Risks related to forward-looking statements includes those risks described in the Company's Annual Information Form dated March 9, 2012 under the heading "Risk Factors" and updated by the Company's short form prospectus dated July 11, 2012 under the headings "Forward-Looking Statements" and "Risk Factors". Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking information in this press release, and, accordingly, investors should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made and the Company undertakes no obligation to update any forward-looking information to reflect the occurrence of unanticipated events, except as required by law. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for management of the Company to predict all of such factors, changes in such factors and to assess in advance the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this press release.
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
Most Popular Stories
- Businesses, Investors Pressing for Green Policy
- E-scrap Recyclers Find Profits in Upgrades
- 'The Voice' Sounds Different This Season
- Congress Casts a Coy Vote on ISIS War
- At Groupon, Not a Good Deal of Workplace Diversity
- Lower Used-Car Prices Roil the Auto Industry
- Utah Hosts US Hispanic Chamber of Commerce Meeting
- Investors Fret Yahoo's Future, Stock Dips
- Liberty Power Helps USHCC Go Green
- Porn Lovers Get a New Search Engine